Current Report Filing (8-k)
August 12 2015 - 04:32PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
August 6, 2015
Albany
Molecular Research, Inc.
(Exact Name of Registrant as Specified in
its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-35622 | |
14-1742717 |
(Commission File Number) | |
(IRS Employer Identification No.) |
26
Corporate Circle, Albany, NY | |
12212 |
(Address of Principal Executive Offices) | |
(Zip Code) |
Registrant’s telephone number, including area code: (518)
512-2000
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
In connection with Albany Molecular Research,
Inc.’s (the “Company”) acquisition of all of the outstanding shares of Gadea Grupo Farmaceutico, S.L. (“Gadea”),
Gadea’s pro forma adjusted EBITDA for the twelve month period ending June 30, 2015 is approximately $25,000,000 based on
accounting principles generally accepted in Spain. The information in this Item 7.01 of this Current Report on Form 8-K
is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Act of 1934,
as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in any such filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALBANY MOLECULAR RESEARCH, INC. |
|
|
|
|
|
|
|
|
|
August 12, 2015 |
By: |
/s/ Lori M. Henderson |
|
|
Name: |
Lori M. Henderson |
|
|
Title: |
Senior Vice-President, General Counsel & |
|
|
|
Secretary |
|
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Mar 2023 to Mar 2024